The estimated Net Worth of Gail S Page is at least $374 millier dollars as of 14 December 2010. Ms. Page owns over 45,000 units of Chembio Diagnostics stock worth over $64,357 and over the last 17 years she sold CEMI stock worth over $266,400. In addition, she makes $43,500 as Executive Chairman of the Board at Chembio Diagnostics.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Page CEMI stock SEC Form 4 insiders trading
Gail has made over 2 trades of the Chembio Diagnostics stock since 2008, according to the Form 4 filled with the SEC. Most recently she sold 45,000 units of CEMI stock worth $266,400 on 14 December 2010.
The largest trade she's ever made was selling 45,000 units of Chembio Diagnostics stock on 14 December 2010 worth over $266,400. On average, Gail trades about 4,525 units every 96 days since 2008. As of 14 December 2010 she still owns at least 139,907 units of Chembio Diagnostics stock.
You can see the complete history of Ms. Page stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gail Page biography
Gail S. Page serves as Executive Chairman of the Board of the Company. Ms. Page was Interim Chief Executive Officer from January 2020 to March 2020 and then provider of transitional services from March 2020 to June 2020, Venture Partner at Turret Capital Management, L.P., an international healthcare-focused investment management fund, since September 2018, Managing Partner and founder of Vineyard Investment Advisors, LLC, a firm assisting with new product and services development, from 2014 to November 2018, Co-founder and director of Consortia Health Holdings LLC, a rehabilitation services provider focused on pelvic disorders, from 2013 to June 2018, President, Chief Executive Officer and director of Vermillion, Inc., a developer and manufacturer of novel diagnostic blood tests, from 2006 to 2012, Executive Vice President and Chief Operating Officer of Luminex Corporation, a developer of testing solutions for life science applications, from 2000 to 2003 and Senior Vice President of Roche Biomedical Laboratories, Inc. / Laboratory Corporation of America, a healthcare diagnostic company, from 1988 to 2000. She holds Bachelor of Science degree in Medical Technology from the University of Florida and Completed executive management program at the Kellogg School in Chicago.
What is the salary of Gail Page?
As the Executive Chairman of the Board of Chembio Diagnostics, the total compensation of Gail Page at Chembio Diagnostics is $43,500. There are 6 executives at Chembio Diagnostics getting paid more, with Javan Esfandiari having the highest compensation of $557,521.
How old is Gail Page?
Gail Page is 64, she's been the Executive Chairman of the Board of Chembio Diagnostics since 2020. There are 1 older and 6 younger executives at Chembio Diagnostics. The oldest executive at Chembio Diagnostics Inc. is Mary Polan, 76, who is the Independent Director.
What's Gail Page's mailing address?
Gail's mailing address filed with the SEC is 555 WIRELESS BOULEVARD, , HAUPPAUGE, NY, 11788.
Insiders trading at Chembio Diagnostics
Over the last 20 years, insiders at Chembio Diagnostics have traded over $909,824 worth of Chembio Diagnostics stock and bought 3,754,893 units worth $1,696,058 . The most active insiders traders include Credit Advisors, Llcpercept..., Lawrence A. Siebert et Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of $36,203. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth $109,552.
What does Chembio Diagnostics do?
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
What does Chembio Diagnostics's logo look like?
Complete history of Ms. Page stock trades at Chembio Diagnostics et Vermillion
Chembio Diagnostics executives and stock owners
Chembio Diagnostics executives and other stock owners filed with the SEC include:
-
Javan Esfandiari,
Exec. VP and Chief Science & Technology Officer -
Richard L. Eberly,
Pres, CEO & Director -
Javan Esfandiari,
Executive Vice President, Chief Scientific And Technology Officer -
Neil Goldman,
Chief Financial Officer, Executive Vice President -
Katherine Davis,
Independent Director -
John Potthoff,
Independent Director -
Gail Page,
Executive Chairman of the Board -
Mary Polan,
Independent Director -
Lynn Lewis,
Investor Relations Contact Officer -
Chuck Caso,
Vice President of Sales and Marketing for North America -
Richard Eberly,
President, Chief Executive Officer, Director -
Stella Rivera,
VP of HR -
Atif Rizvi,
VP of Fin. -
Dr. Konstantin Lyashchenko,
Research Director of Chembio Diagnostic Systems Inc -
Charles Caso,
VP of Sales & Marketing -
Paul J. Angelico,
VP of Global Operations -
Peter Kissinger,
Director -
Richard J Larkin,
Chief Financial Officer -
Barbara A De Buono,
Director -
John J Iii Sperzel,
CEO -
Robert L Aromando,
Sr VP, Commercial Operations -
Alan Carus,
Director -
Lawrence A. Siebert,
President -
Leslie Teso Lichtman,
-
Norman H Pessin Brian L. Pe...,
-
Gary Meller,
Director -
Sharon W Klugewicz,
Chief Operating Officer -
David Gyorke,
See Remarks -
Robert Passas,
See Remarks -
Avi Pelossof,
Vice President -
Gerald A Eppner,
Director -
James D Merselis,
Director -
Capital Master Llc Crestvie...,
-
David Acheson,
-
Credit Advisors, Llcpercept...,
-
David William Bespalko,
-
Lawrence J. Steenvoorden,
See remarks -
Charles Caso,
See Remarks -
Paul Angelico,
See remarks